Literature DB >> 19833757

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.

Michelle Petri1, Sukhminder Singh, Hanna Tesfasyone, Ashima Malik.   

Abstract

OBJECTIVE: We determined the prevalence of and risk factors for British Isles Lupus Activity Group (BILAG) flare in patients with systemic lupus erythematosus (SLE).
METHODS: We followed 299 patients for 1 year with the BILAG scores calculated using British Lupus Integrated Prospective System software and confirmed with manual calculation.
RESULTS: "A" flares occurred at a rate of 0.254/year, "B" flares 1.637/year, and A or B flares 1.765/year. The most common A flares were renal and mucocutaneous. The most common B flares were hematologic, renal, mucocutaneous, and musculoskeletal. Risk factors for a later A or B flare in the hematological system included: low C3 (p < 0.0001), low C4 (p = 0.0004), and positive anti-double-stranded (ds)DNA (p = 0.003); in the mucocutaneous system: low C3 (p = 0.02) and low C4 (p = 0.0004); and in the renal system: low C3 (p = 0.02) and low C4 (p = 0.02). In a stepwise regression model, only ethnicity (p = 0.02) and low C4 (p = 0.0002) remained as independent predictors of later A or 2B flares.
CONCLUSION: The organ system distribution of A and B flares is very different, with A flares more common in renal and mucocutaneous, and B flares more common in hematologic and renal systems. A or 2B flares are significantly more common in African Americans and in patients with abnormal serologies (low C3, low C4, or high anti-dsDNA). If flare is an outcome in an SLE clinical trial, these factors must be balanced by taking them into account at baseline in terms of randomization, or by statistical adjustment in final analyses.

Entities:  

Mesh:

Year:  2009        PMID: 19833757     DOI: 10.3899/jrheum.090019

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

Review 2.  Biomarkers in connective tissue diseases.

Authors:  Neelakshi R Jog; Judith A James
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

Review 3.  Systemic lupus erythematosus biomarkers: the challenging quest.

Authors:  Cristina Arriens; Jonathan D Wren; Melissa E Munroe; Chandra Mohan
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

4.  Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.

Authors:  Liying Peng; Ziqian Wang; Mengtao Li; Yanhong Wang; Dong Xu; Qian Wang; Shangzhu Zhang; Jiuliang Zhao; Xinping Tian; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2017-09-19       Impact factor: 2.980

5.  Pathways of impending disease flare in African-American systemic lupus erythematosus patients.

Authors:  Melissa E Munroe; Evan S Vista; Joan T Merrill; Joel M Guthridge; Virginia C Roberts; Judith A James
Journal:  J Autoimmun       Date:  2017-02-02       Impact factor: 7.094

6.  B cells from African American lupus patients exhibit an activated phenotype.

Authors:  Laurence C Menard; Sium Habte; Waldemar Gonsiorek; Deborah Lee; Dana Banas; Deborah A Holloway; Nataly Manjarrez-Orduno; Mark Cunningham; Dawn Stetsko; Francesca Casano; Selena Kansal; Patricia M Davis; Julie Carman; Clarence K Zhang; Ferva Abidi; Richard Furie; Steven G Nadler; Suzanne J Suchard
Journal:  JCI Insight       Date:  2016-06-16

Review 7.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

8.  Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.

Authors:  Melissa E Munroe; Evan S Vista; Joel M Guthridge; Linda F Thompson; Joan T Merrill; Judith A James
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

Review 9.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

10.  Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Authors:  Zhi-Wei Lai; Rebecca Borsuk; Ashwini Shadakshari; Jianghong Yu; Maha Dawood; Ricardo Garcia; Lisa Francis; Hajra Tily; Adam Bartos; Stephen V Faraone; Paul Phillips; Andras Perl
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.